drugset / Trial / NCT07190469
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Timeline
- Start
- 2025-09-16
- Primary completion
- 2028-12
- Completion
- 2029-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PQ203 | Peptide | — | Intravenous |